Antibodies against citrullinated proteins have emerged as powerful diagnostic and prognostic tools in RA that may contribute to the initiation phases of the disease. The enzymes that catalyze the citrullination process, known as peptidyl argenine deiminases (or PADs), may also be involved in the initiation and propagation steps of the RA disease process. Additionally, autoimmunity to these catalysts may identify a subset of RA patients with unique disease phenotypes.
The T-cell inhibitor efalizumab (Raptiva) has demonstrated efficacy in the treatment of moderate to severe plaque psoriasis. However, it has not demonstrated efficacy for the treatment of psoriatic arthritis and, in one study, was associated with worsening of arthritis symptoms. Only a minority of individuals with psoriasis have a concomitant inflammatory arthritis, making therapy with efalizumab an option for the treatment of a large number of psoriasis patients who have no articular involvement.
Knuckle Cracking Q&A from Johns Hopkins Arthritis Center
Arthritis News > Continuation For TNF Switch High rates of continuation for RA patients switched to second TNF inhibitor January 2007 – Jon Giles, M.D. Clinical trials of TNF inhibitors in rheumatoid arthritis (RA) typically show minimal clinical response rates (i.e. ACR20) of 60 to 70%. However, clinically meaningful response rates, such as an ACR50 […]
Arthritis News > RA & Subclinical Synovitis RA Patients in Remission May Still Have Subclinical Synovitis January 2007 – Jon Giles, M.D. Radiographic progression has been demonstrated in RA patients with no clinical evidence of synovitis on physical examination. This has raised the question of whether joint damage and destruction can occur in the absence […]